Gevokizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Gevokizumab
Accession Number
DB12119  (DB06062)
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states. It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
XOMA 052
Categories
UNII
QX3JU54GYQ
CAS number
1129435-60-4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UInterleukin-1 betaNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Gevokizumab.
AbituzumabThe risk or severity of adverse effects can be increased when Gevokizumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Gevokizumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Gevokizumab.
AducanumabThe risk or severity of adverse effects can be increased when Gevokizumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Gevokizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gevokizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Gevokizumab.
AmatuximabThe risk or severity of adverse effects can be increased when Gevokizumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Gevokizumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911285
Wikipedia
Gevokizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentType 2 Diabetes Mellitus1
1, 2CompletedTreatmentType 2 Diabetes Mellitus1
1, 2WithdrawnTreatmentAutoinflammatory / Behcet's Syndrome / Muckle Wells Syndrome1
2CompletedTreatmentAcne Vulgaris1
2CompletedTreatmentAutoimmune Inner Ear Disease1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 12
2CompletedTreatmentOsteoarthritis (OA)2
2CompletedTreatmentPyoderma Gangrenosum1
2CompletedTreatmentType 2 Diabetes Mellitus2
2SuspendedTreatmentRheumatoid Arthritis1
3TerminatedTreatmentBehcet's Disease Uveitis1
3TerminatedTreatmentBehcet's Uveitis1
3TerminatedTreatmentChronic Uveitis1
3TerminatedTreatmentPyoderma Gangrenosum3
Not AvailableCompletedTreatmentOsteoarthritis (OA)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein domain specific binding
Specific Function
Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, ...
Gene Name
IL1B
Uniprot ID
P01584
Uniprot Name
Interleukin-1 beta
Molecular Weight
30747.7 Da

Drug created on October 20, 2016 15:23 / Updated on November 02, 2018 07:20